OBJECTIVE: This study examined the reliability and validity of the Korean version of the Child Sexual Behavior Inventory (CSBI) in Korean children aged from 6 to 12 years old and the suitability of and potential for clinical application of the CSBI in Korean population. METHODS: The participants consisted of 158 typically growing children and 122 sexually abused children. The subjects were evaluated using the Korean version of the Child Sexual Behavior Inventory (CSBI), the Child Behavior Checklist (CBCL), and the Trauma Symptom Checklist for Young Children (TSCYC). Internal consistency was examined as a measure of reliability. To investigate the concurrent validity, Pearson's correlations were calculated. One-way ANCOVA was used to demonstrate discriminant validity. RESULTS: The Cronbach's alpha value was 0.84. The CSBI total score was moderately correlated with the CBCL subscales and mildly correlated with the sexual concern subscale of the TSCYC. The total score of the CSBI for the sexually abused children group was significantly higher than that of typically growing children group. CONCLUSION: This study demonstrated that the Korean version of the Child Sexual Abuse Inventory (CSBI) is a reliable and valid tool. It can be applied in the clinical field for assessing the sexual behavior of Korean children aged from 6 to 12 who are suspected to have been sexually abused.
Checklist ; Child Abuse, Sexual ; Child Behavior ; Child* ; Humans ; Korea ; Mass Screening ; Reproducibility of Results* ; Sexual Behavior*

OBJECTIVES: Stress can substantially affect the symptoms and courses of mood disorders. Among the various factors of stress perception, one's personality traits and mood states are especially important. The aim of the current study is to examine the influences of personality traits on perceived stress in mood disorder, comparing depressive disorders and bipolar disorders. METHODS: Patients with depressive disorders (n=81) and bipolar disorders (n=79) and who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition diagnostic criteria were recruited. Stress perception was measured using the Perceived Stress Scale (PSS). Personality traits were assessed using the Temperament and Character Inventory and the Neo-Five Factor Inventory. Linear regression analysis was performed to examine and determine the predictors that significantly affect perceived stress. RESULTS: Results of univariate linear regression analysis showed that neuroticism, harm avoidance, and novelty seeking were positively related to the PSS score in patients with bipolar disorder. However, agreeableness, self-directedness, extraversion, cooperativeness, and conscientiousness subscales were negatively related to the PSS score. In depressive patients as well, harm avoidance and neuroticism were positively related to the PSS score. Reward dependence, extraversion, agreeableness, self-directedness, and cooperativeness were negatively related to the PSS score. In multivariate linear analysis, self-directedness and extraversion were negatively associated with the PSS score in bipolar patients. CONCLUSION: These results suggest that personality traits associated with perceived stress may differ according to the subtypes of mood disorders. In addition, consideration of the differences in personality subtypes that affect perceived stress is probably required in order to establish strategies for decreasing perceived stress in mood disorder.
Bipolar Disorder ; Depressive Disorder ; Diagnostic and Statistical Manual of Mental Disorders ; Extraversion (Psychology) ; Humans ; Linear Models ; Mood Disorders* ; Reward ; Temperament

The coexistence of CCND1/IGH and MYC rearrangements in mantle cell lymphoma (MCL) is a rare finding associated with a very poor prognosis. In this study, a patient with blastoid variant (MCL) is reported. The disease was clinically aggressive and refractory to chemotherapy, and the patient only survived for 1 month following diagnosis. Conventional cytogenetic study, FISH, and multicolor FISH (mFISH) demonstrated the involvement of the BCL1/CCND1 locus in a complex translocation, t(3;11)(q25;p15)t(11;14)(q13;q32). In addition, subclonal abnormalities in the 8q24 region, manifested as a t(8;14)(q24;q32)/MYC rearrangement, were identified. To the best of our knowledge, this is the first MCL case in Korea bearing these complex genomic aberrations.
Aged, 80 and over ; Antigens, CD5/*metabolism ; Bone Marrow/immunology/metabolism ; Chromosomes, Human, Pair 11 ; Chromosomes, Human, Pair 14 ; Chromosomes, Human, Pair 3 ; Gene Rearrangement ; Humans ; Immunophenotyping ; In Situ Hybridization, Fluorescence ; Lymphoma, Mantle-Cell/*diagnosis/genetics/immunology ; Male ; Oncogene Proteins, Fusion/*genetics ; Proto-Oncogene Proteins c-myc/*genetics ; Translocation, Genetic

Purpose: The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized phase I/IIa clinical trial. Materials and Methods: Overall, 18 patients with advanced non–small cell lung cancer (NSCLC) and a programmed death ligand 1 tumor proportion score of 1% or greater who had a history of failed frontline platinum-based therapy were randomized (2:1) to receive pembrolizumab every 3 weeks +/– 6 weekly infusions of SNK01 at either 2×109 or 4×109 cells per infusion (pembrolizumab monotherapy vs. SNK01 combination). The primary endpoint was safety, whereas the secondary endpoints were the objective response rate (ORR), progression-free survival (PFS), overall survival, and quality of life. Results: Since no dose-limiting toxicity was observed, the maximum tolerated dose was determined as SNK01 4×109 cells/dose. The safety data did not show any new safety signals when SNK01 was combined with pembrolizumab. The ORR and the 1-year survival rate in the NK combination group were higher than those in patients who underwent pembrolizumab monotherapy (ORR, 41.7% vs. 0%; 1-year survival rate, 66.7% vs. 50.0%). Furthermore, the median PFS was higher in the SNK01 combination group (6.2 months vs. 1.6 months, p=0.001). Conclusion Based on the findings of this study, the NK cell combination therapy may consider as a safe treatment method for stage IV NSCLC patients who had a history of failed platinum-based therapy without an increase in adverse events.